• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine
  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Pharma & Human Health

Pharma & Human Health

Global “sisterhood” seeks to understand what makes a healthy vaginal microbiome

February 12, 2025 Microbiome Times

Vaginas host a complex microcosm of bacteria and yeasts that can fluctuate over time. However, little is known about these microbial communities and their roles in a person’s health, and 9 out of 10 studies […]

Pharma & Human Health

Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

January 27, 2025 Microbiome Times

Vedanta Biosciences today announced the publication of additional results from the Phase 2 CONSORTIUM study for its lead candidate, VE303, which is being evaluated for prevention of recurrent Clostridioides difficile infection (rCDI). The new analyses were published […]

Pharma & Human Health

Changes in microbiome predict risk for sexually transmitted disease

January 22, 2025 Microbiome Times

Women who develop bacterial vaginosis (BV) often later acquire chlamydia, a common and potentially serious sexually transmitted bacterial infection. Now, researchers at Albert Einstein College of Medicine, Roswell Park Comprehensive Cancer Center, and the Icahn School of Medicine at Mount […]

Finance

Owlstone Medical Announces $27 Million USD First Close in Series E Financing Round

January 15, 2025 Microbiome Times

Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced a first closing of $27 million (circa £22 million) in its Series E financing round. The […]

Animal Health

Penn Medicine launches a pioneering project to study the human virome puzzle

January 14, 2025 Microbiome Times

For over a decade, scientists have studied the microbiome, the environment of microorganisms that live on and in the body, and how it affects health and disease. Much less is known about a part of […]

Editor's Choice

MaaT Pharma Announces Positive Results from Pivotal Phase 3 ARES Study

January 8, 2025 Microbiome Times

MaaT Pharma (EURONEXT: MAAT – the “Company”), a late-stage clinical-stage biotechnology company leading the development of Microbiome Ecosystem Therapies TM (MET) to improve survival in cancer patients through modulation of the immune system, today announced topline results from […]

Pharma & Human Health

A new way to determine whether a species will successfully invade an ecosystem

January 7, 2025 Microbiome Times

When a new species is introduced into an ecosystem, it may succeed in establishing itself, or it may fail to gain a foothold and die out. Physicists at MIT have now devised a formula that […]

Pharma & Human Health

Exploring the impact of probiotics on gut microbiota disruption caused by antibiotics

December 17, 2024 Microbiome Times

Antibiotics are important clinical tools for treating bacterial infections, yet we recognize that an important side effect of antibiotic use is disruption of the microbial community living in the human gut. Antibiotics targeted against bacterial […]

Pharma & Human Health

Microbio Announces Promising Results of “MS-20” in Combination with Keytruda for Non-Small Cell Lung Cancer

December 17, 2024 Microbiome Times

Microbio Co., Ltd. (4128) today revealed encouraging results from an exploratory clinical trial of MS-20 combined with Keytruda (pembrolizumab) in stage IIIb/IV non-small cell lung cancer (NSCLC). The trial showed a threefold increase in the […]

Pharma & Human Health

Possible colon cancer vaccine target uncovered in bacteria

December 12, 2024 Microbiome Times

Higher rates of certain cancers in countries, such as the UK, may be linked to two particular strains of bacteria. Targeting these with treatments or vaccines could help reduce the risk of colorectal, bladder, and […]

Finance

SNIPR Biome receives up to €20 million European backing to advance therapies AMR

December 10, 2024 Microbiome Times

Danish biotech SNIPR Biome will get up to €20 venture debt from the European Investment Bank (EIB) to step up Europe’s fight against antimicrobial resistance to medicines. The company will use the EIB credit to […]

Posts navigation

« 1 … 4 5 6 … 84 »

Sign Up to Free Newsletter

Editor’s Choice

  • MRM Health Raises €55 Million Series B to Advance Microbiome-Based Biotherapeutic Product Pipeline
    September 4, 2025
  • Targeting the ileo-colonic region: Innovative solutions for sensitive APIs
    August 21, 2025
  • EXPERT’Biome CDMO by Lallemand at Microbiome Times Forum
    June 23, 2025
  • DynaMAP – Precision Metagenomics beyond Sequencing
    May 27, 2025
  • The Selection of a Pre-Clinical Model is Driven by the Specific Research Question
    May 13, 2025
sign up

Sign up to the Microbiome Times newsletter